Treatment of chronic spontaneous urticaria

Allergy, Asthma and Immunology Research

Volumn 4, Issue 6, 2012, Pages 326-331

  Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anti IgE receptor; Antihistamine; Cyclosporine; Omalizumab; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE;

CHRONIC URTICARIA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; URTICARIA; URTICARIAL VASCULITIS; VASCULITIS;

EID: 84869824587     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2012.4.6.326     Document Type: Review

References (54)

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B. Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-43.
2. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39:777-87.
3. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation. Br J Dermatol 1986;114: 583-90.
4. Grattan CE, Boon AP, Eady RA, Winkelmann RK. The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Appl Immunol 1990;93:198-204.
5. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213-7.
6. Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704.
7. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-604.
8. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996;106:1001-6.
9. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001;107: 1056-62.
10. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004;114:465-74.
11. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104:169-72.
12. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002;109:114-8.
13. Kaplan AP, Joseph K. Basophil secretion in chronic urticaria: autoantibody-dependent or not? J Allergy Clin Immunol 2007;120:729-30.
14. Hancock K, Narang S, Pattabhi S, Yushak ML, Khan A, Lin SC, Plemons R, Betenbaugh MJ, Tsang VC. False positive reactivity of recombinant, diagnostic, glycoproteins produced in High Five insect cells: effect of glycosylation. J Immunol Methods 2008;330:130-6.
15. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998;101: 243-51.
16. Du Toit G, Prescott R, Lawrence P, Johar A, Brown G, Weinberg EG, Motala C, Potter PC. Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria. Ann Allergy Asthma Immunol 2006;96:341-4.
17. Altrich ML, Halsey JF, Altman LC. Comparison of the in vivo autologous skin test with in vitro diagnostic tests for diagnosis of chronic autoimmune urticaria. Allergy Asthma Proc 2009;30:28-34.
18. Ferrer M, Kinét JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672-6.
19. Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005;115:815-21.
20. Ling M, Ge J, Altrich ML, Halsey JF. Importance of antigen selection in the detection of autoantibodies against FcεRIα in chronic urticaria patients [abstract]. J Allergy Clin Immunol 2010;125 Suppl 1:AB30. Abstract no. 118.
21. Vonakis BM, Vasagar K, Gibbons SP Jr, Gober L, Sterba PM, Chang H, Saini SS. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007;119:441-8.
22. Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, Marzano AV, Fanoni D, Cugno M. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007;119:705-10.
23. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008;63:176-80.
24. Kessel A, Bishara R, Amital A, Bamberger E, Sabo E, Grushko G, Toubi E. Increased plasma levels of matrix metalloproteinase-9 are associated with the severity of chronic urticaria. Clin Exp Allergy 2005;35:221-5.
25. Eckman JA, Hamilton RG, Gober LM, Sterba PM, Saini SS. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008;128:1956-63.
26. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM. British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007;37:631-50.
27. Grattan CE, Humphreys F. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007;157:1116-23.
28. Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983;71:177-83.
29. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986;78:914-8.
30. Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, Black MM, Black AK, Greaves MW. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999;103:484-93.
31. Dubuske LM. Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc 2007;28:724-34.
32. Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, Donado E, Perez I, Izquierdo I, Arnaiz E. Rupatadine Urticaria Study Group. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007;62:539-46.
33. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-8.
34. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Martinelli N, Rini GB. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004;114: 619-25.
35. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72-6.
36. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123:672-9.
37. Wanderer AA, St Pierre JP, Ellis EF. Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol 1977;113:1375-7.
38. Sigler RW, Evans R 3rd, Horakova Z, Ottesen E, Kaplan AP. The role of cyproheptadine in the treatment of cold urticaria. J Allergy Clin Immunol 1980;65:309-12.
39. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676-82.
40. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346:175-9.
41. Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009; 123:713-7.
42. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203-17.
43. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, Holgate ST, Zuberbier T. Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459-66.
44. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.
45. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.e1.
46. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3.
47. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66:303-5.
48. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9.e5.
49. Romano C, Sellitto A, De Fanis U, Esposito G, Arbo P, Giunta R, Lucivero G. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol 2010;104:95-7.
50. Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, Berroa F, Kaplan AP. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 2011;127:1300-2.
51. Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black A, Greaves MW. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143:365-72.
52. Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52:312-6.
53. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
54. McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006;142:1337-42.